Patents by Inventor Tina Howden

Tina Howden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods and compositions for reducing adipocyte numbers
    Patent number: 11452703
    Abstract: A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.
    Type: Grant
    Filed: May 21, 2020
    Date of Patent: September 27, 2022
    Assignee: Peregrine Ophthalmic PTE LTD.
    Inventors: Shih-Horng Su, Tina Howden
  • METHODS AND COMPOSITIONS FOR REDUCING ADIPOCYTE NUMBERS
    Publication number: 20210361609
    Abstract: A method for reducing a subcutaneous fat deposit or a visceral fat deposit in vivo by contacting the fat deposit with a composition of latanoprost encapsulated in a liposome formed solely of egg phosphatidylcholine (EggPC) or palmitoyloleoyl phosphatidylcholine (POPC). Also disclosed are methods for treating steatoblepharon, proptosis, and obstructive sleep apnea associated with excess upper airway fat by injecting into the eyelid, intraconal space, and upper airway fat deposit, respectively, the composition of latanoprost encapsulated in an EggPC or POPC liposome.
    Type: Application
    Filed: May 21, 2020
    Publication date: November 25, 2021
    Inventors: Shih-Horng Su, Tina Howden
  • Stable liposomal formulations for ocular drug delivery
    Patent number: 9956195
    Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.
    Type: Grant
    Filed: January 7, 2014
    Date of Patent: May 1, 2018
    Assignees: Nanyang Technological University, Singapore Health Services Pte Ltd
    Inventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Tina Howden, Freddy Boey
  • STABLE LIPOSOMAL FORMULATIONS OF ALPHA 2 ADRENERGIC AGONISTS FOR OCULAR DELIVERY
    Publication number: 20170119666
    Abstract: A stable liposomal formulation for ocular delivery of an alpha 2 adrenergic agonist. The formulation contains a liposome that includes a lipid bilayer including a phosphatidylcholine. An alpha 2 adrenergic agonist is encapsulated in the liposome.
    Type: Application
    Filed: October 29, 2015
    Publication date: May 4, 2017
    Inventors: Ting-Bin Yu, Zhiwei Shi, Shih-Horng Su, Tina Howden
  • STABLE LIPOSOMAL FORMULATIONS OF CARBONIC ANHYDRASE INHIBITORS FOR OCULAR DRUG DELIVERY
    Publication number: 20170042809
    Abstract: A stable liposomal formulation for ocular delivery of a carbonic anhydrase inhibitor. The formulation contains (i) a liposome that includes a lipid bilayer formed of a phosphatidylcholine, and (ii) a carbonic anhydrase inhibitor encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.
    Type: Application
    Filed: August 11, 2015
    Publication date: February 16, 2017
    Inventors: Ting-Bin Yu, Zhiwei Shi, Shih-Horng Su, Tina Howden
  • STABLE LIPOSOMAL FORMULATIONS FOR OCULAR DRUG DELIVERY
    Publication number: 20150190359
    Abstract: A stable liposomal formulation for ocular delivery. The formulation contains a liposome that includes at least one lipid bilayer containing a phosphatidylcholine, and a prostaglandin F2? encapsulated in the liposome. Also provided is a method for treating an ocular disorder with the formulation.
    Type: Application
    Filed: January 7, 2014
    Publication date: July 9, 2015
    Inventors: Subramanian Venkatraman, Jayaganesh V. Natarajan, Tina Howden, Freddy Boey